Andy Hahn: Body composition’s influence on the therapeutic index with ARSI

Andy Hahn, Genitourinary Medical Oncologist at MD Anderson Cancer Centre, shared on X:

“Tweetorial for our latest paper on body composition’s influence on the therapeutic index with ARSI in Prostate Cancer and Prostatic Diseases.

This work was supported by a Conquer Cancer, the ASCO Foundation YIA and established our ongoing research program.

‘Body composition as a determinant of the therapeutic index with androgen signaling inhibition‘

Authors: Andrew W Hahn, Rebecca S Tidwell, Patrick G Pilie, Yao Yu, Jingjing Liu, Devaki Shilpa Surasi, Mark Titus, Jianhua Zhang, Neha Venkatesh, Theocharis Panaretakis, Justin R Gregg, Amado J Zurita, Bilal A Siddiqui, Paul G Corn, Sumit K Subudhi, Pavlos Msaouel, Efstratios Koutroumpakis, Chad D Huff, Ana Aparicio, Jennifer L McQuade, Daniel E Frigo, Christopher J Logothetis.

Steroidogenesis has roles in muscle, fat, and PCa. We studied how inherited variants in steroidogenic genes influenced body composition at time of mCRPC. We found differences in body composition by genotype in AKR1C3, CYP17A1, and SRD5A2 SNPs.

We measured body composition using CTs before tx with ADT + apa + abi (AAPA) in 186 men with mCRPC. We found that elevated subQ and visceral fat were associated with improved PSA response to AAPA and showed how body composition groupings influenced response.

Last, subQ and visceral fat had positive correlations with leptin but not most of the remaining adipokines we tested.

”

Source: Andy Hahn/X